These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 2957898)
1. Vaccine development within industry. De Wilde M Acta Trop Suppl; 1987 Jun; 12():104-7. PubMed ID: 2957898 [No Abstract] [Full Text] [Related]
2. Release potency tests of hepatitis vaccines. Descamps J; Mary A; Rommel E; Anhoury ML; De Neys R; Duchêne M Dev Biol Stand; 1999; 101():289-94. PubMed ID: 10566803 [TBL] [Abstract][Full Text] [Related]
3. Specifications and quality control of a yeast-derived hepatitis B vaccine. Peetermans JH Postgrad Med J; 1987; 63 Suppl 2():97-100. PubMed ID: 3317364 [TBL] [Abstract][Full Text] [Related]
4. Subunit, recombinant and synthetic hepatitis B vaccines. Zuckerman AJ Microbiol Sci; 1985 May; 2(5):129-30, 133-8. PubMed ID: 2978963 [TBL] [Abstract][Full Text] [Related]
5. Innovative vaccine production technologies: the evolution and value of vaccine production technologies. Bae K; Choi J; Jang Y; Ahn S; Hur B Arch Pharm Res; 2009 Apr; 32(4):465-80. PubMed ID: 19407962 [TBL] [Abstract][Full Text] [Related]
6. [Vaccination against hepatitis virus B infection. Vaccine from inactivated HBsAg positive plasma or recombinant vaccine?]. Horejsí J Cas Lek Cesk; 1987 Jul; 126(31):981-2. PubMed ID: 2959363 [No Abstract] [Full Text] [Related]
7. Hepatitis B vaccine. Capiau C Dev Biol Stand; 1998; 96():127-9. PubMed ID: 9890526 [No Abstract] [Full Text] [Related]
8. Hepatitis B vaccines: use in childhood. Moyes CD N Z Med J; 1988 Apr; 101(843):165-6. PubMed ID: 2965800 [No Abstract] [Full Text] [Related]
9. Immunogenicity of a recombinant yeast-derived hepatitis B vaccine (Engerix B) in children. Moyes C; Milne A N Z Med J; 1988 Apr; 101(843):162-4. PubMed ID: 2965799 [TBL] [Abstract][Full Text] [Related]
10. Developments in immunization against hepatitis B. Zuckerman AJ Ann Ist Super Sanita; 1987; 24(2):285-91. PubMed ID: 2969206 [No Abstract] [Full Text] [Related]
11. Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children. Milne A; Moyes CD; Allwood GK; Pearce NE; Krugman S N Z Med J; 1988 Feb; 101(840):67-9. PubMed ID: 2967940 [TBL] [Abstract][Full Text] [Related]
12. Hepatitis B vaccines. N Z Med J; 1988 Dec; 101(859):831. PubMed ID: 2974517 [No Abstract] [Full Text] [Related]
13. [The future of viral hepatitis vaccines]. Shdanov VM Z Gesamte Hyg; 1985 Mar; 31(3):134-7. PubMed ID: 2990115 [No Abstract] [Full Text] [Related]
17. Hepatitis B vaccination and the rate of seroconversion in high risk contacts. Sengupta B; Sarkar A; De M; Lahiri P; Bhattacharya DK J Indian Med Assoc; 1993 Nov; 91(11):281-2, 285. PubMed ID: 8138648 [TBL] [Abstract][Full Text] [Related]
18. Prospects for new viral vaccines. Norrby E Microbiol Sci; 1987 Jul; 4(7):202-5. PubMed ID: 3153612 [TBL] [Abstract][Full Text] [Related]
19. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors]. Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060 [TBL] [Abstract][Full Text] [Related]
20. Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects. Ristola MA; Vuola JM; Valle M; von Reyn CF Vaccine; 2004 Nov; 23(2):205-9. PubMed ID: 15531038 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]